The effect of myo-inositol supplementation on nutritional status, cardiometabolic factors, liver function, oxidative stress, visfatin and hs-CRP levels, gene expression of insulin resistance pathway and HIF1α, NF-kB, TNF-α, Interleukin-1β and 6 in patients with non-alcoholic fatty liver disease.

Inclusion criteria:

Age 18-55 years Body mass index in the range of 30-40 Kg / m2 Willingness to cooperate Hepatic steatosis based on Grade 1 and 2 NAFLD disease

Exclusion criteria:

Athlete, pregnancy, lactation and menopause in women Infertility treatment, taking oral contraceptive pills Smoking and alcohol use Adherence to a special diet 3 months before the study Use of chemical or herbal medicines for weight loss and use of hepatotoxic drugs such as phenytoin, amoxifine , lithium and antihypertensive drugs and lipid-lowering drugs (statins), insulin sensitiser medications Taking antibiotics or dietary supplements that affect the levels of liver enzymes History of weight loss surgery over the last year or rigid weight loss diets three months before the trial Use of corticosteroids and NSAIDs or any type of supplements for 3 months before or during the study Use of any multivitamin (vitamin E and folic acid, etc.), antioxidants (L-arginine, glutamine) and fish oil supplements for 3 months before or during the study those with cardiovascular disease, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary disease, known autoimmune diseases, PCOs, cancers and conditions with mal-absorption such as Sprue and Crohn Having symptoms of a recent infectious, inflammatory disease or recent surgery Candidate or history of Liver transplant Intention for pregnancy

Target sample size: 50